Comparative Pharmacology
Head-to-head clinical analysis: AVOPEF versus XTANDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVOPEF versus XTANDI.
AVOPEF vs XTANDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avopef is a synthetic peptide analog that acts as a selective antagonist of the nociceptin/orphanin FQ (N/OFQ) receptor (NOP), modulating pain pathways and stress responses. It also exhibits partial agonist activity at mu-opioid receptors, contributing to its analgesic and anxiolytic effects.
Androgen receptor inhibitor; binds to the androgen receptor, inhibits nuclear translocation, DNA binding, and transcription of androgen-responsive genes.
Adults: 400 mg intravenously every 8 hours for 7-14 days.
160 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 2.0-3.5 hours; prolonged to 6-12 hours in renal impairment.
Enzalutamide: 5.8 days; active metabolite N-desmethyl enzalutamide: 7.8-8.6 days. Steady state achieved after ~28 days.
Renal: 70-80% unchanged; Biliary/Fecal: 15-20%; minor hepatic metabolism.
Primarily hepatic metabolism; 77% of dose recovered in feces (as metabolites), 15% in urine (as metabolites); less than 1% excreted unchanged.
Category C
Category C
Antineoplastic
Antineoplastic